Can CTC counts be used as surrogate endpoints in clinical trials?

Intermediate or surrogate endpoints for survival can shorten timelines for drug approval. A paper just published on line in Lancet Oncology aimed to assess the value of circulating tumor cell (CTC) counts as a prognostic factor for survival. … READ MORE …

The Tuesday news update: October 28, 2008

Many reader will already have seen or heard reports of the demise of the SELECT prostate cancer prevention trial. In other news today:

  • There is a recent review of trials of diet and dietary supplements
  • Further evidence supports the potential of surrogate markers for prostate cancer mortality
  • Saturation biopsies appear to overestimate the risk of prostate cancer … READ MORE …